Shoaib Shakeel, DO
Pulmonary Disease · Columbus, OHNPI 1790105443
Payments from drug & device makers
Across 62 payments — averaging $75.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Inari Medical, Inc.$195
- AstraZeneca$190
- Boehringer Ingelheim$187
- Johnson & Johnson$139
- Pulmonx Corporation$120
- plus $595 from 15 others
What the payments were for
- Travel & lodging$76316%
- Food & beverage$1,44331%
- Education$2,50053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $3,280 |
| Inari Medical, Inc. | 1 | $195 |
| AstraZeneca | 11 | $190 |
| Boehringer Ingelheim | 10 | $187 |
| Johnson & Johnson(2 entities) | 2 | $139 |
| Pulmonx Corporation | 1 | $120 |
| GSK | 8 | $119 |
| Grifols USA, LLC | 6 | $105 |
| Mylan Specialty L.p. | 3 | $68 |
| Insmed, Inc. | 3 | $47 |
| Pfizer | 2 | $40 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Vertex | 1 | $30 |
| Baxter Healthcare | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| CSL Behring | 1 | $20 |
| Covis Pharma GmbH | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Gilead | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,707 in reported general payments places this provider in the 60th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $131,101 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $34,325 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $30,058 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $22,764 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $14,700 |
| DuleraMometasone/Formoterol | 25 | $9,529 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 21 | $8,481 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,740 |
| EliquisApixaban | 11 | $6,432 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,355 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,154 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 157 | $3,406 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,176 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $3,124 |
| Roflumilast | 15 | $3,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $119 | $188,076275 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $190 | $49,54591 claims |
| PfizerEliquis | $40 | $6,43211 claims |
| Boehringer IngelheimSpiriva Respimat | $187 | $6,35513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Columbus
- Edward CordascoColumbus$8M
- Brian ZenoColumbus$2.9M
- Roy St JohnColumbus$1.9M
- Nitin BhattColumbus$876K
- Matthew ExlineColumbus$386K
- Christian GhattasColumbus$286K
- Alberto ReveloColumbus$232K
- Derrick HermanColumbus$213K
- James FaganColumbus$179K
- Todd AstorColumbus$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.